O’Hearn, Katie
Menon, Kusum
Weiler, Hope A.
Amrein, Karin
Fergusson, Dean
Gunz, Anna
Bustos, Raul
Campos, Roberto
Catalan, Valentina
Roedl, Siegfried
Tsampalieros, Anne
Barrowman, Nick
Geier, Pavel
Henderson, Matthew
Khamessan, Ali
Lawson, Margaret L.
McIntyre, Lauralyn
Redpath, Stephanie
Jones, Glenville
Kaufmann, Martin
McNally, Dayre
,
Funding for this research was provided by:
Canadian Institutes of Health Research
AHSC AFP Innovation Fund
Article History
Received: 27 March 2023
Accepted: 24 July 2023
First Online: 14 August 2023
Declarations
:
: VITdAL-PICU was approved by the Children’s Hospital of Eastern Ontario Research Ethics Board (protocol no. 15/ 18E) on 16-Oct-2015, by the Medical University of Graz Ethics Committee (REB reference 28–619 ex 15/16) on 19-Jan-2017, by the Ethical Scientific Committee of the Concepción Health Service (REB reference 16–03-10) on 24-May-2016, and by the Western University Health Sciences Research Ethics Board (REB number 109099) on 31-Jul-2017. Written informed consent was obtained for each participant by the site investigator or trained delegate prior to any study-related procedures. For participants who were minors (under 16 years of age), informed consent was obtained from a parent and/or legal guardian. Where applicable, assent was also obtained. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: Dr. Khamessan is employed by Euro-Pharm International Canada Inc. Dr. Khamessan and Euro-Pharm International Canada Inc., at the request of the investigative team, developed and prepared the concentrated vitamin D solution used in the study. All other authors have no competing interests as defined by BMC, or other interests that might be perceived to influence the results and/or discussion reported in this paper.